Market News & Trends
Absci Announces Collaboration With AstraZeneca to Advance AI-Driven Oncology Candidate
Absci Corporation recently announced a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. This collaboration combines Absci's Integrated Drug Creation platform…
AbbVie to Acquire ImmunoGen, Including its Flagship Cancer Therapy, Expanding Solid Tumor Portfolio
AbbVie Inc. and ImmunoGen, Inc. recently announced a definitive agreement under which AbbVie will acquire ImmunoGen and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class….
Samsung Bioepis Secures US License Date for SB17, a Proposed Biosimilar to Stelara
Samsung Bioepis Co., Ltd. has recently signed a settlement and license agreement with Johnson & Johnson settling all pending US patent litigation between the two…
Orchard Therapeutics Receives US FDA Fast Track Designation for OTL-203 in MPS-IH
Orchard Therapeutics recently announced the US FDA has granted Fast Track designation to OTL-203, an investigational hematopoietic stem cell gene (HSC) therapy being developed for…
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
Tiziana Life Sciences Ltd. recently announced it has successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigham…
Hovione Expands Nasal Drug Delivery Capabilities With Development of Nasal Powder Delivery Device Technology in Collaboration With IDC
Hovione and Industrial Design Consultancy (IDC) have entered into a joint development of an innovative nasal powder delivery device technology supporting local, systemic, and nose-to-brain drug delivery….
Ardena's New Aseptic Fill-Finish Plant in Ghent Receives GMP License
Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has been granted a Good Manufacturing Practice (GMP) license by the….
BiomX Announces Positive Topline Results From Part 2 of the Phase 1b/2a Trial Evaluating Treatment for Chronic Pulmonary Infections in Patients With Cystic Fibrosis
BiomX Inc. recently announced positive safety and efficacy results from Part 2 of the Phase 1b/2a trial evaluating the company’s novel phage cocktail, BX004, for…
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung
Oxford BioTherapeutics recently announced the US FDA has granted Fast Track designation to BI 764532 for the potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of….
Dyadic Announces Top-Line Results From its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Dyadic International, Inc. recently announced successful top-line results for the Phase 1 clinical trial of its recombinant protein RBD vaccine candidate, DYAI-100. This marks the…
Lumen Bioscience Announces $5.5-Million Funding to Support New Research Program for Mucosal Vaccine Platform Technology
Lumen Bioscience recently announced $5.5 million in new funding from the US Department of Defense, operating through the Medical CBRN Defense Consortium (MCDC), to develop…
Roivant Announces Positive IMVT-1402 Initial 600-mg MAD Results That Confirm Best-in-Class Potential
Immunovant, Inc. recently announced initial data from 600-mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy adults. The results show that…
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration With Bristol Myers Squibb
Global licensing and research collaboration to focus on discovery, development and commercialization of up to five cardiovascular targets leveraging Avidity’s proprietary AOC platform technology….
Evaxion to Unveil Potentially Groundbreaking AI-Immunology Precision Cancer Vaccine Concept
Evaxion Biotech A/S recently announced the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place…
Roivant & Priovant Announce Results From Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Roivant and Priovant recently announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its…
GRI Bio Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for GRI-0621 for the treatment of IPF. The…
Biodexa Enters Agreements to Acquire Exclusive Worldwide License to a Phase 2 Ready Asset for Type 1 Diabetes
Biodexa Pharmaceuticals PLC recently announced it has entered into an agreement for the assignment of Adhera Therapeutics, Inc.’s rights to tolimidone (formerly coded MLR-1023) under an exclusive,….
ADvantage Therapeutics Commences Enrollment for Phase 2b Clinical Trial for Alzheimer’s Disease Treatment
ADvantage Therapeutics, Inc. recently announced the first patient enrolled in the company’s European Phase 2b clinical trial on its lead candidate AD04 for the treatment…
Alladapt Immunotherapeutics Receives FDA Fast Track Designation for the Treatment of Mono- and Multi-Food Allergies
Alladapt Immunotherapeutics, Inc. recently announced that ADP101, its investigational multi-food oral immunotherapy (mOIT) designed to simultaneously treat allergy to one or more of the world’s…
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion & Enrollment of First Patient Into Phase 3 Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Aerovate Therapeutics, Inc. recently announced the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase 2b/Phase 3 study evaluating AV-101,…
